These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21316219)

  • 1. Optimisation of ITK inhibitors through successive iterative design cycles.
    Herdemann M; Weber A; Jonveaux J; Schwoebel F; Stoeck M; Heit I
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1852-6. PubMed ID: 21316219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of potent ITK inhibitors through focused compound library design including structural information.
    Herdemann M; Heit I; Bosch FU; Quintini G; Scheipers C; Weber A
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6998-7003. PubMed ID: 20965724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
    Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase.
    McLean LR; Zhang Y; Zaidi N; Bi X; Wang R; Dharanipragada R; Jurcak JG; Gillespy TA; Zhao Z; Musick KY; Choi YM; Barrague M; Peppard J; Smicker M; Duguid M; Parkar A; Fordham J; Kominos D
    Bioorg Med Chem Lett; 2012 May; 22(9):3296-300. PubMed ID: 22464456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.
    Kim KH; Maderna A; Schnute ME; Hegen M; Mohan S; Miyashiro J; Lin L; Li E; Keegan S; Lussier J; Wrocklage C; Nickerson-Nutter CL; Wittwer AJ; Soutter H; Caspers N; Han S; Kurumbail R; Dunussi-Joannopoulos K; Douhan J; Wissner A
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6258-63. PubMed ID: 21958547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK).
    MacKinnon CH; Lau K; Burch JD; Chen Y; Dines J; Ding X; Eigenbrot C; Heifetz A; Jaochico A; Johnson A; Kraemer J; Kruger S; Krülle TM; Liimatta M; Ly J; Maghames R; Montalbetti CA; Ortwine DF; Pérez-Fuertes Y; Shia S; Stein DB; Trani G; Vaidya DG; Wang X; Bromidge SM; Wu LC; Pei Z
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6331-5. PubMed ID: 24138940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
    Charrier JD; Miller A; Kay DP; Brenchley G; Twin HC; Collier PN; Ramaya S; Keily SB; Durrant SJ; Knegtel RM; Tanner AJ; Brown K; Curnock AP; Jimenez JM
    J Med Chem; 2011 Apr; 54(7):2341-50. PubMed ID: 21391610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay.
    Zapf CW; Gerstenberger BS; Xing L; Limburg DC; Anderson DR; Caspers N; Han S; Aulabaugh A; Kurumbail R; Shakya S; Li X; Spaulding V; Czerwinski RM; Seth N; Medley QG
    J Med Chem; 2012 Nov; 55(22):10047-63. PubMed ID: 23098091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of novel (4 or 5-aryl)pyrazolyl-indoles as inhibitors of interleukin-2 inducible T-cell kinase (ITK).
    Velankar AD; Quintini G; Prabhu A; Weber A; Hunaeus G; Voland B; Wuest M; Orjeda C; Harel D; Varghese S; Gore V; Patil M; Gayke D; Herdemann M; Heit I; Zaliani A
    Bioorg Med Chem; 2010 Jun; 18(12):4547-59. PubMed ID: 20472447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases.
    von Bonin A; Rausch A; Mengel A; Hitchcock M; Krüger M; von Ahsen O; Merz C; Röse L; Stock C; Martin SF; Leder G; Döcke WD; Asadullah K; Zügel U
    Exp Dermatol; 2011 Jan; 20(1):41-7. PubMed ID: 21158938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design.
    Cook BN; Bentzien J; White A; Nemoto PA; Wang J; Man CC; Soleymanzadeh F; Khine HH; Kashem MA; Kugler SZ; Wolak JP; Roth GP; De Lombaert S; Pullen SS; Takahashi H
    Bioorg Med Chem Lett; 2009 Feb; 19(3):773-7. PubMed ID: 19111460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
    Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and structure-activity relationship of indolylindazoles as potent and selective covalent inhibitors of interleukin-2 inducible T-cell kinase (ITK).
    Wang X; Xue G; Pan Z
    Eur J Med Chem; 2020 Feb; 187():111918. PubMed ID: 31830635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Aminobenzimidazoles as potent ITK antagonists: trans-stilbene-like moieties targeting the kinase specificity pocket.
    Lo HY; Bentzien J; Fleck RW; Pullen SS; Khine HH; Woska JR; Kugler SZ; Kashem MA; Takahashi H
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6218-21. PubMed ID: 18930400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk).
    Winters MP; Robinson DJ; Khine HH; Pullen SS; Woska JR; Raymond EL; Sellati R; Cywin CL; Snow RJ; Kashem MA; Wolak JP; King J; Kaplita PV; Liu LH; Farrell TM; DesJarlais R; Roth GP; Takahashi H; Moriarty KJ
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5541-4. PubMed ID: 18823779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors.
    Burch JD; Lau K; Barker JJ; Brookfield F; Chen Y; Chen Y; Eigenbrot C; Ellebrandt C; Ismaili MH; Johnson A; Kordt D; MacKinnon CH; McEwan PA; Ortwine DF; Stein DB; Wang X; Winkler D; Yuen PW; Zhang Y; Zarrin AA; Pei Z
    J Med Chem; 2014 Jul; 57(13):5714-27. PubMed ID: 24918870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and SAR of 2-amino-5-[(thiomethyl)aryl]thiazoles as potent and selective Itk inhibitors.
    Das J; Liu C; Moquin RV; Lin J; Furch JA; Spergel SH; Doweyko AM; McIntyre KW; Shuster DJ; O'Day KD; Penhallow B; Hung CY; Kanner SB; Lin TA; Dodd JH; Barrish JC; Wityak J
    Bioorg Med Chem Lett; 2006 May; 16(9):2411-5. PubMed ID: 16481166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A three-dimensional pharmacophore modelling of ITK inhibitors and virtual screening for novel inhibitors.
    Bagga V; Silakari O; Ghorela VS; Bahia MS; Rambabu G; Sarma J
    SAR QSAR Environ Res; 2011 Mar; 22(1-2):171-90. PubMed ID: 21391146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and structure-activity relationships of a novel class of sulfonylpyridine inhibitors of Interleukin-2 inducible T-cell kinase (ITK).
    Trani G; Barker JJ; Bromidge SM; Brookfield FA; Burch JD; Chen Y; Eigenbrot C; Heifetz A; Ismaili MHA; Johnson A; Krülle TM; MacKinnon CH; Maghames R; McEwan PA; Montalbetti CAGN; Ortwine DF; Pérez-Fuertes Y; Vaidya DG; Wang X; Zarrin AA; Pei Z
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5818-5823. PubMed ID: 25455497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.